文献速递心脑血管急症重症综合管理与镇静镇痛

抗癫痫药物使用对重症老年创伤性脑损伤患者死亡率和早期创伤后癫痫的影响

The Effect of Antiseizure Medication Administration on Mortality and Early Posttraumatic Seizures in Critically Ill Older Adults with Traumatic Brain Injury.
PubMed 文献 · Neurocrit Care · 2022-06-01
一句话结论在65岁及以上ICU创伤性脑损伤患者中,早期使用抗癫痫药物与7天、30天及1年死亡率降低相关,但未降低早期癫痫风险。

本研究为回顾性队列研究,利用MIT的MIMIC-III公开数据集,纳入2001至2012年间在一级创伤中心ICU收治的65岁及以上创伤性脑损伤患者1145例,其中783例(68.4%)在24小时内接受了抗癫痫药物。采用基于比例风险模型和逻辑回归模型的双稳健逆倾向评分加权模型分析,结果显示接受抗癫痫药物者7天死亡风险(调整HR 0.48,95%CI 0.28-0.88,P=0.005)、30天死亡风险(调整HR 0.67,95%CI 0.45-0.99,P=0.045)和1年死亡风险(调整HR 0.72,95%CI 0.54-0.97,P=0.029)均较低,但癫痫风险无显著差异(调整OR 1.18,95%CI 0.61-2.26)。作者认为该获益在轻、中、重度TBI中均可见,提示对任何严重程度的老年TBI患者可考虑更广泛地使用抗癫痫药物。

要点

  • 在65岁及以上ICU创伤性脑损伤患者中,24小时内使用抗癫痫药物与7天死亡率降低独立相关(调整HR 0.48,95%CI 0.28-0.88,P=0.005)。
  • 接受抗癫痫药物者30天死亡率(调整HR 0.67,95%CI 0.45-0.99,P=0.045)和1年死亡率(调整HR 0.72,95%CI 0.54-0.97,P=0.029)也较低。
  • 抗癫痫药物未显著降低早期创伤后癫痫风险(调整OR 1.18,95%CI 0.61-2.26)。
  • 获益在GCS评估的轻度、中度和重度TBI患者中均被观察到,作者据此建议对任何严重程度的老年TBI患者可更广泛地使用抗癫痫药物。
  • 该研究为回顾性队列研究,使用MIMIC-III公开数据集,结果需结合原文局限性解读。

适用人群与场景

  • 年龄65岁及以上、因创伤性脑损伤入住一级创伤中心ICU的患者。
  • 数据来源于2001至2012年MIMIC-III公开数据集。
  • TBI严重程度以入院时GCS分类:轻度71.2%、中度16.8%、重度11.3%。
  • 主要暴露为早期(24小时内)抗癫痫药物使用。

研究设计与关键结果

  • 研究类型为回顾性队列研究,样本量1145例,数据来自MIMIC-III公开数据集,患者为65岁及以上因TBI入住ICU者。
  • 783例(68.4%)在24小时内接受了抗癫痫药物;人群以白人(83.8%)和男性(52.3%)为主,中位年龄81岁(四分位距74-86)。
  • 主要终点7天死亡:接受抗癫痫药物者调整死亡HR=0.48(95%CI 0.28-0.88),P=0.005。
  • 次要终点30天死亡:调整HR 0.67(95%CI 0.45-0.99),P=0.045;1年死亡:调整HR 0.72(95%CI 0.54-0.97),P=0.029。
  • 早期创伤后癫痫:调整癫痫OR 1.18(95%CI 0.61-2.26),组间无显著差异。
  • ICU住院时间和医院住院时间作为次要终点,原文未报告具体结果数值。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,基于在轻度、中度和重度TBI中均观察到的死亡率获益,提示对65岁及以上因TBI入住ICU的患者可考虑更广泛地使用抗癫痫药物,而不论TBI严重程度。
  • 该研究未显示抗癫痫药物降低早期创伤后癫痫风险(调整OR 1.18,95%CI 0.61-2.26)。

指南或共识出处

  • 当前脑创伤基金会(Brain Trauma Foundation)指南支持对重型TBI患者预防性使用抗癫痫药物以降低早期创伤后癫痫(伤后7天内)风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Traumatic brain injury (TBI) is a major cause of morbidity and mortality in the United States. Older adults represent an understudied and growing TBI population. Current Brain Trauma Foundation guidelines support prophylactic antiseizure medication (ASM) administration to reduce the risk of early posttraumatic seizures (within 7 days of injury) in patients with severe TBI. Whether ASM decreases mortality or early seizure risk in this population remains unclear. This study addresses the knowledge gap regarding the impact of ASM administration on the risk of seizure or mortality after TBI in patients more than 65 years of age.

METHODS: This retrospective cohort study used a publicly available data set from the Medical Information Mart for Intensive Care-III from the Massachusetts Institute of Technology. Our cohort included patients 65 years or older with a primary exposure of early ASM administration with TBI resulting in an intensive care unit (ICU) admission in a level I trauma center from 2001 to 2012. A double-robust inverse propensity scale weighted model on the basis of proportional hazard and logistic regression models was created to assess the association between ASM administration and risk of death within 7 days of admission to the ICU. Secondary outcomes included 30-day mortality and 1-year mortality, early posttraumatic seizures, ICU length of stay, and hospital length of stay.

RESULTS: Of 1145 patients 65 years or older with TBI admitted to an ICU, 783 (68.4%) received ASM within the first 24 h. Patients meeting inclusion criteria were predominantly white (83.8%) and were male (52.3%), with a median (interquartile range) age of 81 (74-86) years. TBI severity, classified by Glasgow Coma Score, was predominantly mild (71.2%), followed by moderate (16.8%) and severe (11.3%). Patients who received ASM were less likely to have died at 7 days (adjusted death hazard ratio [HR] = 0.48 [95% confidence interval {CI} 0.28-0.88], P = 0.005), at 30 days (adjusted HR 0.67 [95% CI 0.45-0.99], P = 0.045), and at 1 year (adjusted HR 0.72 [95% CI 0.54-0.97], P = 0.029). Groups were not different in regard to seizure (adjusted seizure odds ratio 1.18 [95% CI 0.61-2.26]) compared with those who did not receive ASM.

CONCLUSIONS: Early ASM administration was associated with reduced mortality at 7 days, 30 days, and 1 year but did not decrease the risk of early seizures among older adults who presented with TBI at an ICU. This benefit was observed in mild, moderate, and severe TBI assessed by Glasgow Coma Score on presentation among patients 65 years old and older and suggests broader recommendations for the use of ASM in older adults who present with TBI of any severity at an ICU.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Glaser AC, Kanter JH, Martinez-Camblor P, et al. The Effect of Antiseizure Medication Administration on Mortality and Early Posttraumatic Seizures in Critically Ill Older Adults with Traumatic Brain Injury. Neurocrit Care. 2022. PMID: 35641806. doi:10.1007/s12028-022-01531-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。